<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialSourcesOutput xmlns:ns2="local"><Sources><Source id="913345" type="PR">Novacea Announces Preliminary Findings From Data Analysis of Ascent-2 Phase 3 Trial</Source><Source id="847746" type="PR">Novacea Halts ASCENT-2 Trial in Advanced Prostate Cancer</Source><Source id="845654" type="PR">Novacea Provides Update on Ascent-2 Protocol Amendment</Source><Source id="661747" type="PR">Novacea Initiates Pivotal Phase 3 Clinical Study of DN-101 in Men With Advanced Prostate Cancer</Source><Source id="1199557" type="SERIAL">Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer</Source><Source id="1592868" type="OTHER">Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial</Source></Sources></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialSourcesOutput>